ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

Medical device company ResMed (NYSE:RMD) announced in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

Paid and presented by Resmed. Day-to-day life for pro surfer Dani means being active and nomadic, so using his CPAP machine to treat and monitor his sleep apnoea means he gets a restful night ...

Piper Sandler analyst Adam Maeder raised the firm’s price target on ResMed (RMD) to $260 from $252 and keeps a Neutral rating on the shares.

Both my parents use CPAP machines to treat their sleep apnea so ... but there are also bundles for ResMed AirSense 10 ($339), Fisher & Paykel ICON ($339), and others. The white sanitizing chamber ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Reports Q2 revenue $1.28B, consensus $1.27B. “Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS ...